$137.8B U.S. ad spend for top 200 advertisers
Windhover’s assets include journals IN VIVO and RPM Report; Strategic Transactions Database, a database of health care industry transactions; and a series of medical device and biopharmaceutical partnering and strategy conferences.
The acquisition expands Elsevier’s so-called work-flow tools. Windhover will operate within Elsevier’s Pharma Business Intelligence Unit, which includes F-D-C Reports and Inteleos, a database on drug development.
Elsevier is a subsidiary of Anglo-Dutch publishing giant Reed Elsevier.